What strategic adjustments did the pharmaceutical market make to the good pharmaceutical companies as a whole in the quarter of 2018?

[market analysis of China Pharmaceutical network] in recent years, with the development of China's society and economy, the level of people's health care services has been further improved, and the pharmaceutical industry has gradually entered a new normal Driven by the "healthy China" strategy and the "Internet plus" wave, Chinese pharmaceutical enterprises are firmly grasping the market opportunities, innovating and developing, and maintaining sustained growth in performance According to the data of the National Bureau of statistics, in the quarter of 2018, the revenue growth rate of pharmaceutical listed companies was 23.7%, and the growth rate of deducting non net profit was 31.1%, a new high in recent years With the overall development of the pharmaceutical market, many multinational pharmaceutical enterprises and local enterprises have also made strategic adjustments to the changes in the market and policies in order to create new profit growth points Zhendong pharmaceutical recently announced that the company is making strategic adjustments to deal with the loss of pharmaceutical trade assets, idle assets, and pipelines with low efficiency, including 5 Pharmaceutical Trade and logistics companies, 2 pharmaceutical companies, with an estimated transaction amount of about 1 billion yuan, which will benefit the main business In the future, the company will strengthen the two core pipelines of tumor and benefit, focus on advantageous resources and improve the company's efficiency According to industry analysis, Zhendong pharmaceutical's "slimming action" is conducive to improving business performance, increasing operating capital, improving cash liquidity and reducing financial costs Focusing on the two major pipelines of tumor and benefit by focusing on advantageous resources is conducive to continuously improving the company's profitability On June 22, at the special meeting of shareholders of LVYE, LVYE successfully voted on the acquisition of 51 countries and regions of AstraZeneca and its sustained-release tablets It is understood that this is a big step for green leaf pharmaceutical to fully open its global strategy LVYE pharmaceutical takes this opportunity to release the company's international cooperation strategy In the future, it will carry out global cooperation in three strategic business areas: global R & D, global manufacturing and global market Sanofi recently announced that Sanofi, a French pharmaceutical company, will establish a global R & D operation center focusing on digital and big data analysis in Chengdu, Sichuan Province, China It is understood that this is the third largest center of Sanofi's global clinical science and operation business, as well as the company's major adjustment to China and even the global strategy It is reported that the R & D operation center costs nearly 600 million yuan, will support the clinical research and development of Sanofi innovative drugs by focusing on the management of global multi center clinical trial data and documents, and will summarize global data and analysis to accelerate the availability of clinical trial results from phase I to phase IV In addition, Sanofi will use local talents to further strengthen its digital capabilities In early June, Pfizer announced the total survival data of the second generation of EGFR targeting drug dacomitinib lung cancer phase III clinical research Archer 1050 at the annual meeting of the American Society of clinical oncology The drug has obtained the priority examination qualification
It is reported that Pfizer will select some early R & D projects that are suitable for the disease spectrum of Chinese patients and have a high demand for treatment Through the forms of intellectual property rights and market authorization, Pfizer will authorize the projects and the accompanying proprietary technology and other resources to local enterprises with R & D strength and innovation potential in relevant fields, and further carry out localized development, with a view to Bring the new drug to the patient as soon as possible In addition to the above pharmaceutical enterprises, there are also many local pharmaceutical enterprises in the process of strategic adjustment, while multinational pharmaceutical enterprises are increasing cooperation with local pharmaceutical enterprises According to the analysis of the industry, only when the downstream consumption demand of the pharmaceutical industry keeps stable growth in the future, can the enterprises in line with the development trend of the industry and the direction of the industry reform occupy an advantage in the industry competition in the future, so as to obtain greater development space With the increasing concentration of the pharmaceutical industry in the future, the effect of "the strong will always be strong" will continue to increase.